VeonGen

VeonGen is a clinical-stage biotechnology company based in Helsinki, Finland, that develops advanced oncolytic virus immunotherapies for the treatment of solid tumors. The company’s proprietary PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) platform combines the natural immunogenicity of oncolytic viruses with the specificity of peptide vaccines to create a potent anti-tumor response. By decorating the viral capsid with tumor-specific peptides, VeonGen’s technology directs the immune system to recognize and attack cancer cells throughout the body. This approach is designed to turn the patient's own tumor into an in situ vaccine, potentially overcoming the challenges of the immunosuppressive tumor microenvironment. VeonGen is a spin-out from the University of Helsinki and is currently progressing its lead candidates through early clinical development. The company's pipeline targets high-unmet-need indications such as melanoma and non-small cell lung cancer.